BIOMM S.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.77 BRL | +10.99% |
|
+8.62% | +207.44% |
| 18/04 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
| 17/04 | Biocon Limited Signs an Exclusive Licensing and Supply Agreement with Biomm S.A | CI |
| Sales 2022 | 105M 20.54M 1.71B | Sales 2023 | 118M 23.13M 1.93B | Capitalization | 470M 91.94M 7.68B |
|---|---|---|---|---|---|
| Net income 2022 | -92M -18M -1.5B | Net income 2023 | -81M -15.85M -1.32B | EV / Sales 2022 | 5.9 x |
| Net Debt 2022 | 67.72M 13.25M 1.11B | Net Debt 2023 | 125M 24.44M 2.04B | EV / Sales 2023 | 5.03 x |
| P/E ratio 2022 |
-5.37
x | P/E ratio 2023 |
-5.93
x | Employees | 130 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 47.6% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +10.99% | ||
| 1 week | +8.62% | ||
| Current month | +74.22% | ||
| 1 month | +74.22% | ||
| 3 months | +243.05% | ||
| 6 months | +281.33% | ||
| Current year | +207.44% |
1 week
15.50
17.83
1 month
9.4218.40
Current year
5.0018.40
1 year
3.6918.40
3 years
3.1018.40
5 years
3.1029.00
10 years
3.1029.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Director of Finance/CFO | - | 16/19/16 | |
Luciano Vilela
CTO | Chief Tech/Sci/R&D Officer | - | 20/14/20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 74 | 01/14/01 | |
| Director/Board Member | 84 | 13/15/13 | |
| Director/Board Member | 81 | 16/13/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/24/29 | 17.77 | +10.99% | 309,100 |
| 26/24/26 | 16.01 | +1.52% | 124,300 |
| 25/24/25 | 15.77 | -3.37% | 130,300 |
| 24/24/24 | 16.32 | +2.00% | 232,600 |
| 23/24/23 | 16 | -2.20% | 200,000 |
Delayed Quote Sao Paulo, April 30, 2024 at 01:36 am IST
More quotes
Biomm SA, formerly Savicevic Participacoes SA, is a Brazil-based company primarily engaged in the biotechnology industry. The Company is principally engaged in the development and licensing of technology for the production of human insulin and other recombinant proteins. The Companyâs technology is suitable for the production of therapeutic proteins, which are used in the production of drugs and biopharmaceuticals. The Companyâs technology for insulin production is protected by patents in various countries in Europe, Asia, North and South America. In addition, it is active in the development of production process of enzymes that are used in the hydrolysis of biomass and in the manufacture of bio-fuel. As of December 31, 2011, the Companyâs subsidiaries were Biomm International Inc, Biomm Middle East Inc and Biomm Russia Ltd.
| 1st Jan change | Capi. | |
|---|---|---|
| +207.44% | 310M | |
| -2.63% | 102B | |
| +1.62% | 96.29B | |
| +1.98% | 22.18B | |
| -16.67% | 21.2B | |
| -8.68% | 18.31B | |
| -38.74% | 17.38B | |
| -13.21% | 16.36B | |
| +5.41% | 13.97B | |
| +33.57% | 12.17B |
- Stock Market
- Equities
- BIOM3 Stock
